Identity, Sterility & Endotoxin Testing Explained
Understanding Pharmaceutical Quality • Laboratory Verification • Research Compound Safety
A Certificate of Analysis (COA) can provide important information about a research compound, but not all laboratory tests evaluate the same characteristics.
A sample may demonstrate high chemical purity while still containing the wrong compound, harmful microorganisms, or bacterial endotoxins.
Understanding the difference between identity testing, purity testing, sterility testing, and endotoxin testing is essential when interpreting laboratory documentation.
For Croix, analytical transparency means understanding exactly what was tested, which sample was examined, what the results establish, and what remains unknown.
RESEARCH EDUCATION • ANALYTICAL QUALITY • LOT SPECIFIC DOCUMENTATION
1. WHY LABORATORY TESTING MATTERS
Research peptides and related compounds are often supplied as lyophilized powders, solutions, or formulated preparations.
Their appearance alone cannot establish their chemical identity, concentration, purity, or microbiological quality.
A vial containing white powder cannot be verified simply by looking at it.
Laboratory testing helps answer several distinct questions:
Identity: Is the substance the compound it is claimed to be?
Purity: How much of the measured chemical material consists of the intended compound?
Content: How much of the intended compound is actually present?
Sterility: Were viable contaminating microorganisms detected under the specified test conditions?
Endotoxins: Is the level of bacterial endotoxin within the applicable acceptance limit?
Each question requires an appropriate analytical method.
A favorable result in one category does not automatically establish favorable results in the others.
2. IDENTITY TESTING
WHAT IS IDENTITY TESTING?
Identity testing examines whether the chemical substance in a sample is consistent with the compound identified on its label.
For peptides, identity is especially important because compounds can have similar names, related amino acid sequences, or different chemical modifications.
Two peptides may be structurally related without being chemically interchangeable.
COMMON IDENTITY TESTING METHODS
Mass Spectrometry (MS)
Mass spectrometry measures characteristics of ions, including their mass-to-charge ratios.
It can help determine whether a compound's molecular mass is consistent with its expected structure.
Liquid Chromatography–Mass Spectrometry (LC-MS)
LC-MS combines chromatographic separation with mass spectrometric analysis.
It can provide information about chemical identity and help distinguish the intended compound from certain impurities.
Tandem Mass Spectrometry (MS/MS)
Tandem mass spectrometry can provide additional structural information through fragmentation patterns.
For peptides, this may help support sequence-related identification when an appropriate validated method is used.
IMPORTANT IDENTITY LIMITATION
A molecular mass consistent with the expected peptide does not necessarily establish the complete amino acid sequence.
Different compounds can share the same or similar molecular masses.
Strong identity verification may require multiple complementary analytical techniques, appropriate reference standards, and validated acceptance criteria.
Identity testing answers what a substance appears to be. It does not, by itself, establish that the substance is sterile, safe, or clinically effective.
3. PURITY TESTING
WHAT DOES PEPTIDE PURITY MEAN?
Chemical purity testing estimates the relative amount of the intended compound compared with other substances detected by a particular analytical method.
High-performance liquid chromatography (HPLC) is commonly used to evaluate peptide purity.
HOW HPLC WORKS
HPLC separates compounds according to how they interact with a chromatography column and mobile phase.
A detector records signals as different components pass through the system.
The resulting chromatogram may show a principal peak associated with the intended compound and smaller peaks associated with impurities or degradation products.
UNDERSTANDING A 99% PURITY RESULT
A report showing 99% HPLC purity often means that the principal peak represents approximately 99% of the integrated peak area under the stated analytical conditions.
It does not necessarily mean that 99% of the total vial mass consists of active peptide.
Depending on the method, the measurement may not fully account for:
Water content
Residual solvents
Counterions and salts
Excipients
Undetected impurities
Substances that do not respond to the selected detector
PURITY VS. CONTENT
These are different measurements.
Purity describes the relative chemical composition measured by a particular method.
Content or assay estimates the amount of the intended compound in the sample.
A product may show high chromatographic purity but contain less active compound than the label claims.
For example, a vial labeled 10 mg could have a high-purity peptide sample but contain only 8 mg of the intended compound.
The purity result alone would not reveal that discrepancy.
High purity is not the same as verified dosage, content, or product quality.
4. STERILITY TESTING
WHAT IS STERILITY?
Sterility refers to the absence of viable microorganisms.
Sterility testing is particularly relevant to products intended for sterile pharmaceutical applications.
Microbial contamination may involve bacteria, fungi, or other viable organisms.
USP <71> STERILITY TESTING
USP General Chapter <71> describes compendial sterility testing procedures for applicable pharmaceutical products.
Methods commonly involve exposing a sample to specified growth media under controlled incubation conditions and observing for evidence of microbial growth.
Depending on the product and validated method, testing may use membrane filtration or direct inoculation.
WHAT DOES “NO GROWTH” MEAN?
A report stating No Growth means that microbial growth was not detected under the conditions of the test.
This is useful information, but it has limitations.
Sterility testing evaluates a sample rather than proving with absolute certainty that every unit in a batch is free from microorganisms.
Results depend on:
Sampling procedures
Test method suitability
Sample quantity
Incubation conditions
The organisms detectable under the method
Proper laboratory execution
DOES A PASSING STERILITY TEST GUARANTEE SAFETY?
No.
A passing sterility test does not establish that a product is free from bacterial endotoxins, chemical impurities, or other hazards.
It also does not replace validated sterile manufacturing processes, environmental controls, container-closure integrity, or appropriate quality assurance.
A sterility result is one part of microbiological quality assessment, not a guarantee of overall product safety.
5. ENDOTOXIN TESTING
WHAT ARE ENDOTOXINS?
Bacterial endotoxins are components associated with the outer membranes of Gram-negative bacteria.
They are primarily composed of lipopolysaccharides.
Endotoxins can trigger inflammatory responses in humans.
Significant exposure may be associated with fever, chills, hypotension, and potentially serious systemic reactions.
CAN ENDOTOXINS REMAIN AFTER BACTERIA ARE KILLED?
Yes.
This is one of the most important distinctions in pharmaceutical quality testing.
A preparation may contain no detectable viable bacteria while still containing bacterial endotoxins.
Killing bacteria does not necessarily eliminate their endotoxins.
Consequently, a product may pass a sterility test but fail an endotoxin test.
COMMON ENDOTOXIN TESTING METHODS
Limulus Amebocyte Lysate (LAL)
LAL-based assays are established methods for detecting or quantifying bacterial endotoxins.
USP <85> Bacterial Endotoxins Test
USP General Chapter <85> describes compendial bacterial endotoxin testing approaches and requirements.
Other appropriately validated methods may also be used, subject to applicable regulatory and compendial requirements.
UNDERSTANDING ENDOTOXIN UNITS
Endotoxin results are often reported in Endotoxin Units, abbreviated EU.
Depending on the report, results may be expressed as:
EU/mL
EU/mg
EU/vial
These units are not interchangeable without additional information.
For example, an endotoxin result expressed in EU/mg must be interpreted in relation to the relevant amount of material and the applicable exposure limit.
WHAT IS AN ACCEPTABLE ENDOTOXIN LEVEL?
There is no single numerical endotoxin limit that applies universally to every product.
Applicable limits depend on factors such as the intended route of administration, maximum exposure, product specifications, and relevant regulatory standards.
A laboratory result should therefore be evaluated against a scientifically justified acceptance criterion.
A passing endotoxin result does not establish chemical identity, purity, sterility, or clinical safety.
6. IDENTITY VS. PURITY VS. STERILITY VS. ENDOTOXINS
TestPrimary questionWhat it does not establishIdentityIs this the expected compound?Purity, sterility, safetyPurityWhat proportion of detected chemical material is the intended compound?Total active content, sterilityContent / AssayHow much intended compound is present?Microbiological qualitySterilityWas viable microbial contamination detected?Absence of endotoxinsEndotoxinsWhat level of bacterial endotoxin was measured?Absence of viable microorganisms
These tests are complementary.
No single result provides a complete characterization of a pharmaceutical or research product.
7. HOW TO READ A CERTIFICATE OF ANALYSIS
A Certificate of Analysis is a laboratory document reporting analytical findings for a particular sample or lot.
When reviewing a COA, the following information is especially important.
PRODUCT IDENTITY
Does the report identify the same compound as the product being evaluated?
Related peptide names should not automatically be treated as equivalent.
PRODUCT STRENGTH
Does the reported sample correspond to the labeled vial strength?
A COA for a 5 mg product should not automatically be presented as verification of a separate 10 mg product.
LOT OR BATCH NUMBER
Does the laboratory report identify the lot or batch associated with the product?
SAMPLE IDENTIFICATION
Is there a unique sample ID that allows the laboratory report to be traced to the submitted material?
LABORATORY INFORMATION
Does the report identify the testing laboratory?
Are the methods and laboratory credentials appropriate for the claims being made?
REPORT DATE
When was the sample tested, and does the report correspond to the relevant production lot?
ANALYTICAL METHODS
Which techniques were used?
Examples include LC-MS, HPLC, USP <71> sterility testing, and bacterial endotoxin assays.
RESULTS AND ACCEPTANCE CRITERIA
Does the report provide numerical findings where applicable?
Does it identify the acceptance criteria used to determine a passing or failing result?
IMPORTANT DOCUMENTATION PRINCIPLE
A COA should be interpreted according to the actual tests performed and the specific sample identified.
It should not be used to make broader claims that the laboratory did not evaluate.
8. WHY LOT SPECIFIC DOCUMENTATION MATTERS
Laboratory testing is sample-specific.
Two vials carrying the same product name may come from different manufacturing batches.
Even when the intended formulation is identical, manufacturing conditions, storage, handling, and material quality may differ.
This is why lot traceability is essential.
THE CROIX DOCUMENTATION STANDARD
Croix's research documentation standard requires matching:
Product name
Labeled strength
Lot or batch number
Sample identification
Testing laboratory
Report date
When a matching laboratory report is unavailable, the appropriate disclosure is:
No matching Certificate of Analysis is currently displayed.
This statement communicates the documentation status without implying that testing has occurred or that an unrelated laboratory report verifies the product.
WHY A COA CANNOT BE TRANSFERRED BETWEEN LOTS
A COA for one tested sample does not establish the composition, purity, sterility, safety, efficacy, or characteristics of another sample, lot, batch, or product.
This remains true even when the products share the same name or nominal strength.
9. COMMON MISCONCEPTIONS ABOUT PEPTIDE TESTING
“99% PURE MEANS THE PRODUCT IS SAFE.”
Incorrect.
High chromatographic purity does not establish sterility, endotoxin status, correct content, or clinical safety.
“A STERILITY PASS MEANS THERE ARE NO ENDOTOXINS.”
Incorrect.
Endotoxins can remain even when viable bacteria are not detected.
“A COA PROVES EVERY VIAL IN THE BATCH IS IDENTICAL.”
Incorrect.
Laboratory results characterize the submitted sample and must be interpreted within the sampling and quality-control system.
“LC-MS CONFIRMS EVERYTHING ABOUT A PEPTIDE.”
Incorrect.
LC-MS can provide valuable chemical identification information, but the strength of identity confirmation depends on the analytical method and supporting evidence.
“RESEARCH USE ONLY MEANS TESTING IS UNNECESSARY.”
Incorrect.
Research-use designation does not eliminate the importance of accurate identity, composition, or laboratory documentation.
“A PASSING COA MEANS FDA APPROVAL.”
Incorrect.
A Certificate of Analysis is not FDA approval.
Analytical quality, regulatory status, and clinical effectiveness are separate considerations.
10. WHY THESE DISTINCTIONS MATTER FOR RESEARCH
Reliable research depends on knowing what substance is being studied.
If a compound is mislabeled, contaminated, degraded, or present at an unexpected concentration, experimental results may be difficult to interpret or reproduce.
Identity and purity testing help researchers evaluate chemical characteristics.
Content testing helps characterize the amount of material present.
Sterility and endotoxin testing address different aspects of microbiological quality.
Together, these analytical categories can improve transparency and support better interpretation of research materials.
However, even comprehensive laboratory testing does not establish that a substance is appropriate for human administration.
Clinical safety and effectiveness require separate scientific evidence.
SELECTED RESEARCH & REGULATORY REFERENCES
United States Pharmacopeia
USP General Chapter <71> — Sterility Tests.
Compendial reference describing sterility testing methods and requirements.
United States Pharmacopeia
USP General Chapter <85> — Bacterial Endotoxins Test.
Compendial reference describing bacterial endotoxin testing.
United States Pharmacopeia
USP General Chapter <621> — Chromatography.
General reference for chromatographic analytical methods.
U.S. Food & Drug Administration
Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice.
Regulatory guidance addressing sterile manufacturing and quality controls.
U.S. Food & Drug Administration
Pyrogen and Endotoxins Testing: Questions and Answers.
Regulatory guidance concerning bacterial endotoxin testing and applicable considerations.
U.S. Food & Drug Administration
FDA Highlights Concerns with Using Dietary Ingredient Glutathione to Compound Sterile Injectables. 2019.
Safety communication illustrating the importance of appropriate endotoxin specifications and injectable product quality.
U.S. Food & Drug Administration
Current Good Manufacturing Practice regulations, 21 CFR Parts 210 and 211.
Regulatory framework addressing pharmaceutical manufacturing and quality systems.
RESEARCH & EDUCATIONAL INFORMATION
This article is provided for scientific and educational reference.
Laboratory testing can characterize important aspects of a research compound, but no individual analytical result establishes overall product safety, suitability for injection, or clinical effectiveness.
Identity, purity, content, sterility, and endotoxin testing evaluate different properties and should not be treated as interchangeable.
Croix presents analytical documentation only when a corresponding laboratory report can be matched to the specific sample or lot being represented.
A Certificate of Analysis for one sample does not establish the composition, purity, sterility, safety, efficacy, or characteristics of another sample, lot, batch, or product.
Analytical transparency is an important component of responsible research, but it is not a substitute for pharmaceutical quality assurance, regulatory approval, or clinical evidence.